首页
登录
职称英语
Last year, when President George W. Bush announced that federal funds could b
Last year, when President George W. Bush announced that federal funds could b
游客
2025-01-03
14
管理
问题
Last year, when President George W. Bush announced that federal funds could be used to support re search on human embryonic stem cells, he mandated that only those cell lines that existed at the time would qualify for such support. More than a year later it’s becoming increasingly clear that these existing cell lines are inadequate. Unless more are created, the research slowdown may exact a staggering cost in terms of human suffering.
Since this announcement, the U. S National Institutes of Health has tried to stimulate research on the existing cell lines with new funding and efforts to streamline the initially cumbersome process of obtaining approved cells. However, whether there are 60 cell lines, as originally stated, or nine, as now appear to be available to NIH-funded investigators, the number is not adequate. Given the genetic diversity within the population, scientists need access to new cell lines if they are to come up with the most effective cell therapies.
The issue is partly one of safety. In conducting research with human participants, we must minimize risks. The most effective cell line might not be the safest. When developing a new medicine, a large number of molecules must be screened to find a balance between effectiveness and safety. The same is true with cells: In the context of cell therapy, it will be important to minimize unwanted immune reactions and inflammation. This requires selection from a large number of cell lines to obtain the best match.
It’s clear from experiments with animals that stem--cell therapies can reduce human suffering. Parkinsonian mice have been cured with embryonic stem cells that were programmed to become dopamine-secreting, replacement nerve cells. Soon, cells induced to make insulin in tissue cultures will be used in attempts to treat diabetic mice. Similar successes have been achieved in animal models of spinal cord injury, heart failure and other degenerative disorders. We are at a frontier in medicine where tissues will be re stored in ways that were not imaginable just a few years ago. The ethical issues raised by human-embryo research are profound. The human costs of restricting this research must be taken into account as well. The cost in dollars of delaying new stem-cell research is difficult to estimate. It might measure in the hundreds of billions of dollars, especially if one adds the lost productivity of individuals who must leave work to care for victims of degenerative disorders.
A less obvious, but real, cost is the damage to the fabric of America’s extraordinary culture of inquiry and technical development in biomedical science. Our universities and teaching hospitals are unparalleled. We attract the very best students, scientists and physicians from around the world. But these institutions are fragile. Research and education play key roles in attracting the best physicians. A crippled research enterprise might add an unbearable stress with long-lasting effects on the entire system. If revolutionary new therapies are delayed or outlawed, we could be set back for years, if not decades.
To steer clear of controversy, some investigators will redirect their research. Others will emigrate to countries where such research is allowed and encouraged. Some will drop out entirely. The pall cast over the science community could extend far beyond stem-cell research. Many therapies have emerged from collaboration between government-sponsored researchers and private enterprise. Few of these discoveries would have emerged ii, for instance, recombinant DNA research had been outlawed 30 years ago. We face the same type of decision today with limits placed on human embryonic stem cells.
Safeguards will be necessary. But if we do not proceed embracing the values of objective, open, inquiry with complete sharing of methods and results, the field will be left to less rigorous fringe groups here and abroad. Patients and society will suffer. [br] It can he inferred from the first paragraph that the author ______.
选项
A、is in favor of stem-cell research.
B、welcomes the research slowdown.
C、takes a neutral stand on the research.
D、thinks it essential to speed up the research.
答案
A
解析
推断题。由题干定位至首段。末句指出:如果找不到更多的细胞株,研究就会停下来,这会让人们遭受极大的痛苦。可见,作者是认同体细胞研究的,故[A]为答案。[B]与此矛盾,排除。首段未提及加快研究速度,[D]无依据,排除。
转载请注明原文地址:https://tihaiku.com/zcyy/3897363.html
相关试题推荐
Lastyear,whenPresidentGeorgeW.Bushannouncedthatfederalfundscouldb
Lastyear,whenPresidentGeorgeW.Bushannouncedthatfederalfundscouldb
[originaltext]Thefront-runnerinthepresidentialelectioninHaitiRenePr
[originaltext]TheAmericanVicePresidentDickCheneyhassaidheacceptsfu
IntheUnitedStateseducationpoliciesaredeterminedby______.A、thefederalg
[originaltext]TheTreasuryDepartmentannouncedtodaythatitisloweringth
[originaltext]TheTreasuryDepartmentannouncedtodaythatitisloweringth
[originaltext]ThepresidentofAfghanistanHamidKarzaihasdemandedthatth
[originaltext]TheBolivianpresidentCarlosMesahasannouncedhisresignati
[originaltext]PresidentBushsaysAmericaneedstofocusonresearchanddev
随机试题
Aboutthetimethatschoolsandothersquitereasonablybecameinterestedin
低渗性缺水补充钠盐的计算公式,正确的是A.需补钠量(mmol)=[130mmol
南非是世界上唯一一个有三个首都的国家,行政、司法、立法首都是下列()三个城市。A
下列选项中,符合《招标投标法》关于开标规定的是()。A.开标时间和地点,
关于买空交易和卖空交易,以下表述错误的是( )。A.买空交易和卖空交易都会放大
顿咳的好发季节是A.春、夏 B.春、秋 C.夏、秋 D.秋、冬
A.加液研磨法B.水飞法C.超微粉碎法D.低温粉碎E.混合粉碎将物料与干冰或液化
目前,应用最多的数据库是(),这类数据库管理系统产品占据了市场和应用的主导地位
交互式教学模式要教给学生的学习策略有()。 A.总结B.提问C.析疑
效果难于或不能货币化,或货币化的效果不是项目目标的主体时,在经济评价中应采用(
最新回复
(
0
)